Literature DB >> 29661880

Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.

Travis Wassermann1, Eleanor K Reimer2, Marie McKinnon2, Wendy Stock3.   

Abstract

Entities:  

Keywords:  fungal infections; hypokalemia; posaconazole

Mesh：

Substances：

Year:  2018        PMID： 29661880      PMCID： PMC6021675          DOI： 10.1128/AAC.02605-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

Review 1.  Current options in antifungal pharmacotherapy.

Authors:  John Mohr; Melissa Johnson; Travis Cooper; James S Lewis; Luis Ostrosky-Zeichner
Journal:  Pharmacotherapy       Date:  2008-05       Impact factor: 4.705

2.  Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.

Authors:  Maryam Mahmood; Omar Abu Saleh; M Rizwan Sohail
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia.

Authors:  George R Thompson; Diana Chang; Rebecca R Wittenberg; Ian McHardy; Alison Semrad
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

6.  Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Authors:  Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 7.  A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.

Authors:  H Hof
Journal:  Mycoses       Date:  2006       Impact factor: 4.377
  7 in total
  3 in total

1.  Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.

Authors:  Huan-Huan Ji; Xue-Wen Tang; Ni Zhang; Ben-Nian Huo; Ying Liu; Lin Song; Yun-Tao Jia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

2.  Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.

Authors:  Minh-Vu H Nguyen; Matthew R Davis; Rebecca Wittenberg; Ian Mchardy; John W Baddley; Brian Y Young; Alex Odermatt; George R Thompson
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

Review 3.  Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.

Authors:  Megan E Klatt; Gregory A Eschenauer
Journal:  J Fungi (Basel)       Date:  2021-01-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.